Alan Mendelsohn



E-Posters by Alan Mendelsohn
Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
Melinda Gooderham, Kim A Papp, Andrew Blauvelt, Diamant Thaçi, Alan M Mendelsohn, Jeff Parno, Kristian Reich
Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
Stephen K Tyring, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Alan M Mendelsohn, Jeff Parno, Scott Guenthner
Incidence of cardiovascular events among tildrakizumab-treated patients with psoriasis: Pooled data from 3 large randomized clinical trials
Incidence of cardiovascular events among tildrakizumab-treated patients with psoriasis: Pooled data from 3 large randomized clinical trials
Robert Bissonnette, Pablo Fernández-Peñas, Lluís Puig, Alan M Mendelsohn, Stephen J Rozzo, Alan Menter
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Data from 3 randomized clinical trials
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Data from 3 randomized clinical trials
Melinda Gooderham, Boni E Elewski, David M Pariser, Howard Sofen, Alan M Mendelsohn
Outcomes of pregnancies from the tildrakizumab phase 1–3 clinical development program
Outcomes of pregnancies from the tildrakizumab phase 1–3 clinical development program
Kathleen Haycraft, Douglas DiRuggiero, Stephen J Rozzo, Alan M Mendelsohn, Tina Bhutani